This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
The AASLD and the Infectious Diseases Society of America have updated their guidelines and resources for the diagnosis and treatment of hepatitis C virus infection, according to a press release.
The updated guidelines, posted on their website HCVguidelines.org, will reflect recent FDA drug approvals of Mavyret (glecaprevir/pibrentasvir, AbbVie) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir, Gilead Sciences), include a primer on HCV resistance, and provide direction on treating people after kidney transplantation and managing HCV in pregnant women and children, according to the release.
“The new AASLD-IDSA Hepatitis C Guidelines are a refreshing update to one of the most useful tools on the internet for those treating hepatitis C in practice,” Michael S. Saag, MD, associate dean for global health at University of Alabama at Birmingham School of Medicine, Jim Straley Chair in AIDS research, director of the Center for AIDS Research and Co-Editor in Chief of HCV Next, said in an interview. “The tables are well designed, the information easy to access, the website is easy to navigate, and the text provides solid scientific back up to the recommendations.”